News CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:16 2026-09-07 EDT			5-day change	1st Jan Change
9.680 ^HKD	-0.05%		+4.76%	+14.83%

09-01	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China	MT
09-01	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China	MT

All News

Mentions Relevance

09-01	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China	MT
09-01	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China	MT
09-01	CSPC Pharma Initiates Depression Drug Candidate Trial in China	MT
09-01	CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial Of SYH2056 Tablets For The Treatment Of Depression In China	CI
09-01	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 For Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma	CI
08-31	CSPC Pharma Begins Trial for Weight Management Drug in China	MT
08-31	Cspc Pharmaceutical Group Limited Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China	CI
08-28	Cspc Pharmaceutical Group Limited Initiates Phase Ii Clinical Trial of Syh2069 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China	CI
08-27	CSPC Pharma Gets Trial Nod for Weight Management Drug in China	MT
08-27	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For SYH2092 Injection	CI
08-26	CSPC Pharma's Colorectal Cancer Drug Candidate Gets Fast Track Designation by US FDA	MT
08-26	CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint	MT
08-26	CSPC Pharmaceutical Group Limited Reports Sys6090 Grants Fast Track Designation by U.S. Fda for Treatment of Patients with Mss/Pmmr Mcrc	CI
08-26	CSPC Pharmaceutical Group Limited Reports SYS6010 Meets Primary Endpoint In Phase III Clinical Study For EGFR-Mutated NSCLC	CI
08-25	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Recombinant Respiratory Syncytial Virus Vaccine SYS6057 In The U.S	CI
08-24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy	MT
08-21	UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50	MT
08-20	CSPC Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-20	CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%	MT
08-20	Cspc Pharmaceutical Group Limited Declares Interim Dividend for 2026, Payable on 10 November 2026	CI
08-19	CSPC Pharmaceutical Group Limited Initiates Phase Ib/II Clinical Trial of SYS6090 Injection for Treatment of Hepatocellular Carcinoma at First Centre in China	CI
08-18	CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China	MT
08-18	CSPC Pharmaceutical Group Limited Announces New Drug Application for Anbenitamab and Docetaxel for Injection (Albumin-Bound) for First-Line Treatment of Advanced Breast Cancer Accepted by NMPA	CI
08-12	CSPC Pharmaceutical Group Limited Provides Update on the Collaboration, Option and License Agreement with Astrazeneca for the Development of siRNA Drugs	CI
08-11	CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus	MT